A multi-scale approach to colorectal cancer: from a biochemical- interaction signaling-network level, to multi-cellular dynamics of malignant transformation. Interplay with mutations and onco-protein inhibitor drugs.

This review article is part of a special Current Cancer Drug Targets issue devoted to colorectal cancer and molecularly targeted treatments. In our paper we made an attempt to connect more basic aspects with preclinical, pharmacological / therapeutic and clinical aspects. Reconstruction of a Molecular Interaction Map (MIM) comprising an important part of the G0 - G1 - S cell cycle transition, was a major component of our review. Such a MIM serves also as a convenient / organized database of a large set of important molecular events. The frequency of mutated / altered signaling-proteins indicates the importance of this signaling-network region. We have considered problems at different scale levels. Our MIM works at a biochemical-interaction level. We have also touched the multi-cellular dynamics of normal and aberrant colon crypts. Until recently, dynamic simulations at a biochemical or multi-cellular scale level were considered as a sort of esoteric approach. We tried to convince the reader, also on the basis of a rapidly growing literature, mostly published in high quality journals, that suspicion towards simulations should dissipate, as the limitations and advantages of their application are better appreciated, opening the door to their permanent adoption in everyday research. What is really required is a more interdisciplinary mentality and an interdisciplinary approach. The prize is a level of understanding going beyond mere intuition.

[1]  B. Morson,et al.  Colonic adenomas--a colonoscopy survey. , 1979, Gut.

[2]  L. M. Franks,et al.  Introduction to the cellular and molecular biology of cancer , 1986 .

[3]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[4]  S. Roberts,et al.  Measurement of in vivo proliferation in human colorectal mucosa using bromodeoxyuridine. , 1992, Gut.

[5]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[6]  Mucosa-specific DNA adducts in human small intestine: a comparison with the colon. , 1994, Carcinogenesis.

[7]  K. Okazaki,et al.  The Mos/MAP kinase pathway stabilizes c‐Fos by phosphorylation and augments its transforming activity in NIH 3T3 cells. , 1995, The EMBO journal.

[8]  Fos Family Members Induce Cell Cycle Entry by Activating Cyclin D1 , 1998, Molecular and Cellular Biology.

[9]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[10]  Frank McCormick,et al.  β-Catenin regulates expression of cyclin D1 in colon carcinoma cells , 1999, Nature.

[11]  K. Kohn Molecular interaction map of the mammalian cell cycle control and DNA repair systems. , 1999, Molecular biology of the cell.

[12]  M. Karin,et al.  AP-1 in cell proliferation and survival , 2001, Oncogene.

[13]  M. Loeffler,et al.  Cell migration and organization in the intestinal crypt using a lattice‐free model , 2001, Cell proliferation.

[14]  M. Yaniv,et al.  The mammalian Jun proteins: redundancy and specificity , 2001, Oncogene.

[15]  Martin A. Nowak,et al.  The role of chromosomal instability in tumor initiation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[17]  U. Landegren,et al.  Protein detection using proximity-dependent DNA ligation assays , 2002, Nature Biotechnology.

[18]  Christopher S Potten,et al.  The intestinal epithelial stem cell. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  Reinhart Heinrich,et al.  The Roles of APC and Axin Derived from Experimental and Theoretical Analysis of the Wnt Pathway , 2003, PLoS biology.

[20]  Patrick J. Paddison,et al.  siRNAs and shRNAs: skeleton keys to the human genome. , 2003, Current opinion in molecular therapeutics.

[21]  W. Bodmer,et al.  Bottom-up histogenesis of colorectal adenomas: origin in the monocryptal adenoma and initial expansion by crypt fission. , 2003, Cancer research.

[22]  C. Potten,et al.  The small intestine as a model for evaluating adult tissue stem cell drug targets 1 , 2003, Cell proliferation.

[23]  C. Compton,et al.  APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q1 , 2004, Cancer biology & therapy.

[24]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[25]  Patrick J. Paddison,et al.  Cloning of short hairpin RNAs for gene knockdown in mammalian cells , 2004, Nature Methods.

[26]  John N Weinstein,et al.  Molecular Interaction Maps--A Diagrammatic Graphical Language for Bioregulatory Networks , 2004, Science's STKE.

[27]  Patrick J. Paddison,et al.  Short hairpin activated gene silencing in mammalian cells. , 2004, Methods in molecular biology.

[28]  N. Komarova Cancer, aging and the optimal tissue design. , 2005, Seminars in cancer biology.

[29]  J. Lilien,et al.  The regulation of cadherin-mediated adhesion by tyrosine phosphorylation/dephosphorylation of beta-catenin. , 2005, Current opinion in cell biology.

[30]  H. Clevers,et al.  Wnt control of stem cells and differentiation in the intestinal epithelium. , 2005, Experimental cell research.

[31]  Walter Birchmeier,et al.  Balancing cell adhesion and Wnt signaling, the key role of β-catenin , 2006 .

[32]  Hans Clevers,et al.  Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.

[33]  J. Weinstein,et al.  Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. , 2005, Molecular biology of the cell.

[34]  Sean J. Morrison,et al.  Asymmetric and symmetric stem-cell divisions in development and cancer , 2006, Nature.

[35]  Barbara Di Ventura,et al.  From in vivo to in silico biology and back , 2006, Nature.

[36]  J. Weinstein,et al.  Depicting combinatorial complexity with the molecular interaction map notation , 2006, Molecular systems biology.

[37]  D. Lauffenburger,et al.  Physicochemical modelling of cell signalling pathways , 2006, Nature Cell Biology.

[38]  R. Jaenisch,et al.  New advances in iPS cell research do not obviate the need for human embryonic stem cells. , 2007, Cell stem cell.

[39]  R. Jaenisch,et al.  Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. , 2007, Genes & development.

[40]  Julie A. Wilkins,et al.  Myc deletion rescues Apc deficiency in the small intestine , 2007, Nature.

[41]  Edda Klipp,et al.  Constraint-Based Modeling and Kinetic Analysis of the Smad Dependent TGF-β Signaling Pathway , 2007, PloS one.

[42]  G. Parmigiani,et al.  A multidimensional analysis of genes mutated in breast and colorectal cancers. , 2007, Genome research.

[43]  S. Gabriel,et al.  High-throughput oncogene mutation profiling in human cancer , 2007, Nature Genetics.

[44]  B. Kholodenko,et al.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.

[45]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[46]  David Zhang,et al.  The crosstalk between EGF, IGF, and Insulin cell signaling pathways - computational and experimental analysis , 2009, BMC Systems Biology.

[47]  Paul A. Bates,et al.  Mathematical modeling identifies Smad nucleocytoplasmic shuttling as a dynamic signal-interpreting system , 2008, Proceedings of the National Academy of Sciences.

[48]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[49]  C. Yeang,et al.  Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[51]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[52]  L. Ricci-Vitiani,et al.  Colon cancer stem cells , 2009, Journal of Molecular Medicine.

[53]  E. Gerner,et al.  Combination Chemoprevention for Colon Cancer Targeting Polyamine Synthesis and Inflammation , 2009, Clinical Cancer Research.

[54]  Luca Cardelli,et al.  Computational modeling of the EGFR network elucidates control mechanisms regulating signal dynamics , 2009, BMC Systems Biology.

[55]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[56]  H. Clevers,et al.  Single Lgr5 stem cells build crypt–villus structures in vitro without a mesenchymal niche , 2009, Nature.

[57]  Gary R. Mirams,et al.  An integrative computational model for intestinal tissue renewal , 2009, Cell proliferation.

[58]  Leyla Isik,et al.  Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.

[59]  Jens Timmer,et al.  Systems-level interactions between insulin–EGF networks amplify mitogenic signaling , 2009, Molecular systems biology.

[60]  Albert-László Barabási,et al.  Scale-Free Networks: A Decade and Beyond , 2009, Science.

[61]  D. Lauffenburger,et al.  Input–output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data , 2009, Molecular systems biology.

[62]  Allon M Klein,et al.  Intestinal Stem Cell Replacement Follows a Pattern of Neutral Drift , 2010, Science.

[63]  Boris N. Kholodenko,et al.  Ligand-Specific c-Fos Expression Emerges from the Spatiotemporal Control of ErbB Network Dynamics , 2010, Cell.

[64]  P. Arbuthnot,et al.  Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators , 2010, Expert opinion on drug delivery.

[65]  Hans Clevers,et al.  Intestinal Crypt Homeostasis Results from Neutral Competition between Symmetrically Dividing Lgr5 Stem Cells , 2010, Cell.

[66]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[67]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[68]  T. Jacks,et al.  Tissue-specific p19Arf regulation dictates the response to oncogenic K-ras , 2010, Proceedings of the National Academy of Sciences.

[69]  S Parodi,et al.  Dynamic simulations of pathways downstream of ERBB-family, including mutations and treatments: concordance with experimental results. , 2010, Current cancer drug targets.

[70]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[71]  Young Jik Kwon,et al.  Efficient and targeted delivery of siRNA in vivo , 2010, The FEBS journal.

[72]  Sabine Tejpar,et al.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.

[73]  R. Ketting The many faces of RNAi. , 2011, Developmental cell.

[74]  E. Alsberg,et al.  Localized, Targeted, and Sustained siRNA Delivery† , 2011, Chemistry.

[75]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[76]  R. King,et al.  Vigilance and validation: Keys to success in RNAi screening. , 2011, ACS chemical biology.